| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/23/2004 | WO2004080375A2 Vaccine therapy of atherosclerosis |
| 09/23/2004 | WO2004060320A8 Methods of improving health-related quality of life in individuals with systemic lupus erythematosus |
| 09/23/2004 | WO2004047735A3 Broad spectrum anti-viral therapeutics and prophylaxis |
| 09/23/2004 | WO2004037847A3 Hiv envelope-cd4 complexes and hybrids |
| 09/23/2004 | WO2004019921A3 Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases |
| 09/23/2004 | WO2004016231A3 PROTECTION OF PATIENTS LACKING A FUNCTIONAL SPLEEN AGAINST S. PNEUMONIAE WITH PNEUMOCOCCAL SURFACE PROTEIN A (PspA) |
| 09/23/2004 | WO2004010947A3 Humanized antibodies against human 4-1bb |
| 09/23/2004 | WO2003106621A3 Anti-igf-i receptor antibody |
| 09/23/2004 | WO2003094836A3 Methods and products for enhancing immune responses using imidazoquinoline compounds |
| 09/23/2004 | WO2003086175A3 Compositions and methods for the therapy and diagnosis of lung cancer |
| 09/23/2004 | WO2003072017A3 Macromolecular conjugates and processes for preparing same |
| 09/23/2004 | WO2003046204A3 Humanized collagen antibodies and related methods |
| 09/23/2004 | US20040186280 Comprises brachyspira membrane protein B (BmpB) for diagnosing and treating swine dysentery; veterinary medicine |
| 09/23/2004 | US20040186274 Methylation of histone h4 at arginine 3 |
| 09/23/2004 | US20040186175 Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds |
| 09/23/2004 | US20040186067 Vectors and methods for immunization or therapeutic protocols |
| 09/23/2004 | US20040185563 Antigen presenting cells, method for their preparation and their use for cancer vaccines |
| 09/23/2004 | US20040185546 enzyme inhibitor for selectin mediated binding events and methods of treating disease conditions using animal models; genetic engineering |
| 09/23/2004 | US20040185527 Isolated human transporter proteins nucleic acid molecules encoding human transporter proteins and uses thereof |
| 09/23/2004 | US20040185507 Isolated monoclonal antibody comprising a light and heavy chain variable of given sequence; diagnosing, treating and preventing prostate/colon cancer and renal carcinoma |
| 09/23/2004 | US20040185496 Anti-bacterial methods and materials |
| 09/23/2004 | US20040185091 High pressure spray-dry of bioactive materials |
| 09/23/2004 | US20040185083 Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products |
| 09/23/2004 | US20040185064 Method of vaccination through serotype rotation |
| 09/23/2004 | US20040185062 Comprising Bordetella bronchiseptica p68 antigen and adjuvant; veterinary medicine |
| 09/23/2004 | US20040185061 Redox reversible HCV proteins with native-like conformation |
| 09/23/2004 | US20040185058 Immunogenic polypeptides physically linked; anticarcinogenic, antitumor, antiallergen, and viricidal agents; autoimmune diseases; systemic or mucosal vaccines; genetic engineering |
| 09/23/2004 | US20040185057 Therapeutical vaccination |
| 09/23/2004 | US20040185056 Vaccines containing bovine herpesvirus 1 attenuated by mutation in latency-related gene |
| 09/23/2004 | US20040185055 Transcutaneous immunostimulation |
| 09/23/2004 | US20040185054 Chemically programmable immunity |
| 09/23/2004 | US20040185052 Antitumor agents; leukemia; |
| 09/23/2004 | US20040185049 Administering to animal an interleukin-27R/cytokine receptor (IL-27R/WSX-1) ligand to treat autoimmune diseases; antiasthmatics, antiallergens, and antiinflammatory agents; diabetes |
| 09/23/2004 | US20040185048 Modulation of IL-2- and IL-15-mediated T cell responses |
| 09/23/2004 | US20040185046 Methods of treating autoimmune disease via CTLA-4Ig |
| 09/23/2004 | US20040185045 FcgammaRIIB-specific antibodies and methods of use thereof |
| 09/23/2004 | US20040185044 Use of human antibody which recognises apolipoprotein CIII; atherosclerosis or dyslipidaemia treatment; passive vaccination |
| 09/23/2004 | US20040185034 anti-inflammatory cytokines, such as IL-4, IL-10 and chemokines, to induce development of suppressor activity in T cells |
| 09/23/2004 | US20040185033 Tumor antigens and CTL clones isolated by a novel procedure |
| 09/23/2004 | DE10310261A1 Identifizierung von Antigen-Epitopen Identification of antigen epitopes |
| 09/23/2004 | CA2812817A1 Purification process |
| 09/23/2004 | CA2759072A1 Allergen peptide fragments and use thereof |
| 09/23/2004 | CA2519083A1 Allergen peptide fragments and use thereof |
| 09/23/2004 | CA2518944A1 Inhibitors of extracellular hsp90 |
| 09/23/2004 | CA2518787A1 Antibody against tumor specific antigen as target |
| 09/23/2004 | CA2518669A1 Purification process |
| 09/23/2004 | CA2518552A1 Novel compositions and methods for the treatment of immune related disease |
| 09/23/2004 | CA2518549A1 Soluble hybrid prion proteins and their use in the diagnosis, prevention and treatment of transmissible spongiform encephalopathies |
| 09/23/2004 | CA2518275A1 Humanized antibodies that recognize beta amyloid peptide |
| 09/23/2004 | CA2518262A1 Uses of il-23 agonists and antagonists; related reagents |
| 09/23/2004 | CA2517498A1 Adjuvanted bovine vaccines |
| 09/23/2004 | CA2517439A1 Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| 09/23/2004 | CA2516919A1 Influenza virus vaccine |
| 09/23/2004 | CA2515286A1 Immunogenic cd19 ligand-antigenic molecule complexes and fusion proteins |
| 09/22/2004 | EP1460132A1 Antibodies with specific immunoreactivity to thyroid carcinoma cells |
| 09/22/2004 | EP1459768A2 Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| 09/22/2004 | EP1459766A1 Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
| 09/22/2004 | EP1459762A1 Preventives remedies for proliferative organ diseases chronic arthritic diseases hypertrophic scar or keloid |
| 09/22/2004 | EP1459761A1 A pharmaceutical kit comprising anti-human seminal plasma protein single chain antibody/human carboxypeptidase fusion protein and prodrug |
| 09/22/2004 | EP1459760A1 Immunopotentiating inosine monophosphate 5'-nucleotidase resistant derivatives and uses thereof |
| 09/22/2004 | EP1459756A1 REMOVAL PROMOTERS AND INHIBITOR FOR APOPTOSIS CELLS i IN VIVO /i |
| 09/22/2004 | EP1459070A2 Methods for diagnosis and treatment of epithelial-derived cancers, such as colorectal cancers and kidney cancers |
| 09/22/2004 | EP1458883A2 Screening method for agents useful in treating diabetes |
| 09/22/2004 | EP1458861A2 Ides, an igg-degrading enzyme of streptococcus pyogenes |
| 09/22/2004 | EP1458857A1 Hxhv virus, nucleic material, peptide material and uses |
| 09/22/2004 | EP1458853A2 Methods of donor specific crossmatching |
| 09/22/2004 | EP1458851A1 An avian embryo particulate biomass for the production of virus antigens |
| 09/22/2004 | EP1458759A2 Human antibodies against human glycoprotein vi and their use |
| 09/22/2004 | EP1458754A2 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control |
| 09/22/2004 | EP1458753A1 Modified bacterial surface layer proteins |
| 09/22/2004 | EP1458752A2 Polypeptides of pseudomonas aeruginosa |
| 09/22/2004 | EP1458751A2 Antigens for actinobacillus pleuropneumoniae and methods thereof |
| 09/22/2004 | EP1458750A2 Mutated hiv tat |
| 09/22/2004 | EP1458411A2 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 09/22/2004 | EP1458410A2 Stabilised mrna tumour vaccine |
| 09/22/2004 | EP1458404A1 Polyphenol inhibition of nucleoside diphosphate kinase-b activity and cancer metastasis |
| 09/22/2004 | EP1458362A2 Pharmaceutical compositions in particulate form |
| 09/22/2004 | EP1458242A2 Polyvalent conjugate vaccine for cancer |
| 09/22/2004 | EP1301238B1 Needles coated with vaccine |
| 09/22/2004 | EP1187631B1 Prevention of type 1 diabetes and other non-polio enterovirus diseases |
| 09/22/2004 | EP1187629B1 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| 09/22/2004 | EP1140160B1 Method for producing autogenous vaccines for treating chlamydial infections in mammals and humans |
| 09/22/2004 | EP1096955B1 Uses of antibodies to aminophospholipids for cancer treatment |
| 09/22/2004 | EP0990044B1 A method for in vitro molecular evolution of protein function |
| 09/22/2004 | EP0941121B1 Stable lyophilized pharmaceutical substances from monoclonal or polyclonal antibodies |
| 09/22/2004 | EP0914442B1 Avian polynucleotide vaccine formula |
| 09/22/2004 | EP0854925B1 THE NucA PROTEIN OF HAEMOPHILUS INFLUENZAE AND THE GENE ENCODING THAT PROTEIN |
| 09/22/2004 | EP0771355B1 A method for large scale plasmid purification |
| 09/22/2004 | EP0726914B1 Cell surface protein expressed on human cortical thymocyte and their use |
| 09/22/2004 | EP0706571B1 Tuberculosis vaccine |
| 09/22/2004 | EP0587805B2 Bovine herpesvirus type 1 deletion mutants, vaccines based thereon, diagnostic kits for detection of bovine herpesvirus type 1 |
| 09/22/2004 | CN1531653A Method for identification of proteins from intracellular bacteria |
| 09/22/2004 | CN1531600A New polynucleotides and polypeptides of IFN 2-21 gene |
| 09/22/2004 | CN1531554A Humanized antibodies derived from DD-3B6-22, specific for D-dimer fragment of fibrin |
| 09/22/2004 | CN1531553A WT1 modified peptide |
| 09/22/2004 | CN1531548A Chimeric chains that code for proteins that induce effects directed against viruses |
| 09/22/2004 | CN1531440A Pharmaceutical composition for preventing or treating TH1 and TH2 cell related diseases by modulating TH/TH2 ratio |
| 09/22/2004 | CN1531438A Normalization of defective T cell responsiveness through manipulation of thymic regeneration |
| 09/22/2004 | CN1531424A SN-38 lipid complexes and methods of use |
| 09/22/2004 | CN1530440A Monocolone antibody, encoding gene, its uses and hybrid nodule cell line for cecreting same |